Searchable abstracts of presentations at key conferences in endocrinology

ea0085p71 | Miscellaneous 2 | BSPED2022

Evaluation of a new multidisciplinary clinic for the endocrine assessment of patients with duchenne muscular dystrophy

Malhotra Neha , Sarkozy Anna , Allgrove Jeremy , Brain Caroline , Manzur Adnan , Chesover Alexander D

Introduction The endocrine assessment of children with Duchenne muscular dystrophy (DMD) can be necessary for management of osteoporosis, delayed puberty, obesity, adrenal insufficiency, and short stature. With ongoing implementation of the international standards of care for DMD, referrals to our Metabolic Bone Clinic (MBC) increased beyond its capacity, impacting patient care. The neuromuscular and endocrine departments implemented a new referral pathway and Multidis...

ea0086p185 | Bone and Calcium | SFEBES2022

Finding the Culprit: A Rare Case of Oncogenic Osteomalacia

Rahim Haaris , Halim Sandra , Mulla Kaenat , Avari Parizad , Freudenthal Bernard , Comninos Alexander , Cox Jeremy

Oncogenic ostemalacia is a rare paraneoplastic syndrome characterised by renal phosphate wasting secondary to secretion of FGF-23 from mesenchymal tumours. Localisation of the tumour is wanted, as resection can lead to complete clinical and biochemical cure. We present a case of a 57 year old woman with a background of Vitamin D deficiency and secondary hyperparathyroidism, who presented with severe generalised aches and pain, worst in her ribs and thighs, such that she could ...

ea0086p275 | Reproductive Endocrinology | SFEBES2022

Follicle Sizes That are Most Likely to Yield Oocytes During In Vitro Fertilisation (IVF) Treatment

Alhamwi Toulin , Abbara Ali , Hanassab Simon , Comninos Alexander , Kelsey Tom , Salim Rehan , Heinis Thomas , Dhillo Waljit

Background: Infertility affects 1 in 6 couples causing devastating psychological impact. In vitro fertilisation (IVF) treatment can aid couples to conceive, but personalisation of treatment is needed to optimise patient outcomes. Machine learning can aid in the analysis of large complex datasets such as those encountered during IVF treatment. One example is in determining the optimal follicle size on the day of trigger to maximise the number of oocytes collected. Both follicle...

ea0087oc2 | Oral Communications | UKINETS2022

Glucagonomas: diagnostic features and outcomes of first line treatment in a series of 18 patients

Porto Juliana , Branton Alexander , Heseth Richard , Mandair Dalvinder , Caplin Martyn , Toumpanakis Christos

Introduction: Glucagonomas are rare functional pancreatic neuroendocrine tumours (p NETs), with an annual occurrence of 0.01 to 0.1 new cases per 100,000. Objective: We focused on presenting symptoms, primary’s size and location, presence of metastases, biomarkers at diagnosis, histology, response to first line treatment (clinical and biochemical), disease fee survival (DFS) and PFS (progression free survival). Methods: Eighteen pa...

ea0087p14 | Poster Presentations | UKINETS2022

Somatostatin receptors in olfactory neuroblastoma: The rationale for peptide receptor radionuclide therapy

Porto Juliana , Hayes Aimee , Branton Alexander , Caplin Martyn , Alusi Martyn , Grossman Ashley

Olfactory neuroblastoma (ONB) is a rare neuroendocrine tumour with a slow onset of symptoms, and classically a propensity for recurrence and a poor prognosis. Due to its rarity, there is no agreed standard therapy, but treatment will usually include surgical resection, adjuvant radiotherapy and/or chemotherapy. However, such tumours very often show positive uptake on somatostatin receptor radionuclide scanning, and selective use of peptide receptor radionuclide therapy (PRRT) ...

ea0090oc11.3 | Oral Communications 11: Late Breaking | ECE2023

Effects of semaglutide, PYY3-36, antagonists of the GLP-1/NPY-Y2 receptors, and empagliflozin on non-alcoholic fatty liver disease

Haerting Niklas , Herzog Gloria , Nickel Alexander , Kohlhaas Michael , Fassnacht Martin , Ziegler Christian , Dischinger Ulrich

Background: Non-alcoholic fatty liver disease (NAFLD) is a common comorbidity in obese individuals. GLP-1 agonists, such as semaglutide, and SGLT-2 inhibitors, such as empagliflozin, are well known to be beneficial in NAFLD, while other incretins, like peptide tyrosine tyrosine 3-36 (PYY3-36), might be also useful for the treatment of NAFLD. We directly compared the effects of semaglutide alone and in combination with peptide tyrosine tyrosine 3-36 (PYY3-36), empagliflozin and...

ea0090rc11.2 | Rapid Communications 11: Late Breaking | ECE2023

COVID-19 vaccination and Graves’ disease: A population based, matched case-control study

Gorshtein Alexander , Turjeman Adi , Duskin-Bitan Hadar , Leibovici Leonard , Robenshtok Eyal

Objective: Vaccination against coronavirus disease 2019 (COVID-19) an important component of coping with the pandemic. Anecdotal cases and case series reported an association between COVID-19 vaccination and the development of Graves’ disease. We used data from Israel’s largest health care organization to determine whether COVID-19 vaccination was associated with the incidence of Graves’ disease.Methods: We analyzed data from Clalit Health...

ea0090p119 | Endocrine-related Cancer | ECE2023

Improvement of Lung NET Management through standardized Care – a Swiss nationwide observational Study

Schmidlin Moira , Sadowski Samira , Siebenhuner Alexander , Wild Damian , Christ Emanuel , Refardt Julie

Introduction/ Background: Typical (TC) and atypical carcinoids (AC) are the most common neuroendocrine tumors (NETs) of the lung. Being a rare disease, the management of these tumors varies widely among Swiss centers. The impact of guidelines introduced in 2015 is unknown.Aims: Comparison of the management of Swiss patients before and after the publication of the expert consensus of the European Neuroendocrine Tumor Society (ENETS) in 2015.<p class="...

ea0090p715 | Reproductive and Developmental Endocrinology | ECE2023

A systematic review of gonadotropin and GnRH therapy for the induction or completion of puberty in males with hypogonadotropic hypogonadism

Alexander Emma , Faruqi Duaa , Farquhar Robert , Unadkat Ayesha , Ng Yin Kyla , Kokotsis Vasilis , Howard Sasha

Background and aims: Hypogonadotropic hypogonadism is characterised by inadequate secretion of gonadotropins (luteinising hormone (LH) and follicle-stimulating hormone (FSH)) leading to absent, partial or arrested puberty. In males, classical treatment with testosterone promotes virilisation but does not facilitate testicular growth or spermatogenesis. Conversely, treatment with gonadotropins or gonadotropin-releasing hormone (GnRH) stimulates Sertoli and Leydig cells directly...

ea0090p260 | Late-Breaking | ECE2023

Effects of semaglutide, PYY3-36, and empagliflozin on the adrenal gland transcriptome in diet induced obese rats

Kloock Simon , Oertel Marie , Kohlhaas Michael , Nickel Alexander , Fassnacht Martin , Christian G. Ziegler , Dischinger Ulrich

Background: An activation of the hypothalamic-pituitary-adrenal (HPA) axis is a common observation in obese individuals. GLP-1 agonists, such as semaglutide, and SGLT-2 inhibitors, such as empagliflozin, are well known to be beneficial in obesity, while other incretins, like peptide tyrosine tyrosine 3-36 (PYY 3-36), might be also useful for the treatment of obesity. However, the effect of these substances on the adrenal gland is largely unknown. We directly compared the effec...